K-Glim-Trio 1mg Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, each contributing distinct mechanisms to optimize blood glucose regulation. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing fasting and postprandial blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, promoting improved glucose uptake by muscle cells. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, mitigating postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, enhancing patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin and Voglibose. K-Glim-Trio is indicated for adult patients inadequately controlled on diet, exercise, and monotherapy or dual therapy with these agents. It should be used under medical supervision, with regular monitoring of blood glucose, renal function, and hepatic parameters. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. This combination therapy offers a comprehensive approach to glycemic management by targeting multiple pathophysiological defects in type 2 diabetes.